FocalTherics (NASDAQ:FOCL) CEO Ryan Rhodes Acquires 21,000 Shares of Stock

FocalTherics (NASDAQ:FOCL) CEO Ryan Rhodes acquired 21,000 shares of the stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $4.75 per share, with a total value of $99,750.00. Following the completion of the purchase, the chief executive officer directly owned 626,649 shares in the company, valued at approximately $2,976,582.75. This trade represents a 3.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

FocalTherics Stock Down 8.4%

FOCL stock opened at $4.36 on Tuesday. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. The firm has a market cap of $163.41 million, a P/E ratio of -4.23 and a beta of -0.04. The business’s fifty day moving average price is $5.38. FocalTherics has a 52 week low of $1.30 and a 52 week high of $6.40.

FocalTherics (NASDAQ:FOCL) last issued its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The firm had revenue of $13.20 million during the quarter. FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. As a group, analysts expect that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday. Mizuho set a $15.00 price target on shares of FocalTherics and gave the company an “outperform” rating in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a research note on Tuesday, June 2nd. Finally, Piper Sandler reissued a “neutral” rating and issued a $4.00 price objective on shares of FocalTherics in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.75.

Hedge Funds Weigh In On FocalTherics

A number of institutional investors and hedge funds have recently bought and sold shares of FOCL. Flax Pond Capital LLC purchased a new stake in shares of FocalTherics during the fourth quarter valued at approximately $2,623,000. Rock Springs Capital Management LP lifted its position in shares of FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after purchasing an additional 91,500 shares in the last quarter. SmartHarvest Portfolios LLC purchased a new position in shares of FocalTherics in the first quarter valued at $38,000. Leonteq Securities AG purchased a new position in shares of FocalTherics in the fourth quarter valued at $313,000. Finally, Kovack Advisors Inc. acquired a new stake in FocalTherics during the 4th quarter valued at $53,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

Trending Headlines about FocalTherics

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: Company insiders collectively purchased 116,000 shares at $4.75 per share, representing approximately $551,000 of open-market buying. The purchases included CEO Ryan Rhodes, CFO Kenneth S. Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and Directors Lance Willsey, Joshua Levine, Fran Schulz, and David R. Horn. The coordinated buying may suggest that management and directors view the recent weakness as an attractive entry point. FocalTherics insider transaction filing
• Positive Sentiment: Director Lance Willsey made the largest purchase, acquiring 50,000 shares for $237,500. CEO Ryan Rhodes also bought 21,000 shares for $99,750, while several other executives and directors increased their holdings by between 2.83% and 196.08%. FocalTherics director transaction filing
• Negative Sentiment: FocalTherics recently reported quarterly earnings of a $0.39-per-share loss, missing the consensus estimate for a $0.20 loss by $0.19. Revenue was $13.20 million, while the company posted a negative net margin of 56.26% and negative return on equity of 175.45%. Analysts expect a full-year loss of approximately $0.78 per share, which remains a key risk for the stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.